Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stellate Ganglion Block for Major Depressive Disorder
NCT04727229Phase 4Completed
- Sponsor
- Unity Health Toronto
- Start
- Sep 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bupivacaine in major depressive disorder (MDD), sponsored by Unity Health Toronto. Started Sep 2021; status: completed.
02
Drugs
bupivacaine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04727229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04727229.